Form 4: Passage BIO Director Granted Significant Stock Options

Passage BIO, Inc. Director Thomas Richard Kassberg was granted 143,789 stock options with an exercise price of $0.3598, vesting based on service and company milestones.

Summary

• Thomas Richard Kassberg, a Director of Passage BIO, Inc. (PASG), was granted 143,789 Director Stock Options.
• The exercise price for these options is $0.3598 per share.
• The options were granted on May 28, 2025, and are set to expire on May 28, 2035.
• Vesting of the stock options will occur on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2026 Annual Meeting of stockholders, contingent on Mr. Kassberg's continuous service to the issuer.

Sentiment

Score: 6

Explanation: The document reports a standard insider equity grant, which is generally viewed as a positive for aligning director incentives with shareholder value, but does not contain performance-related information that would significantly alter sentiment.

Positives

• The grant of 143,789 stock options to a director aligns management incentives with shareholder interests, encouraging long-term value creation.
• The long expiration date of May 28, 2035, provides a significant window for the director to realize potential value from the options, indicating a long-term perspective.

Negatives

• NA

Risks

• The ultimate value of the stock options is contingent on the future market price of Passage BIO, Inc. common stock exceeding the exercise price of $0.3598.
• Vesting of the options is subject to the director's continuous service to the issuer, meaning the options could be forfeited if service ceases before vesting conditions are met.

Future Outlook

The vesting schedule for the stock options, tied to the one-year anniversary of the grant or the 2026 Annual Meeting, implies an expectation of continued service and commitment from the director to the company's long-term objectives.

Management Comments

• NA

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain key talent, and align their financial interests with the long-term performance and strategic goals of the company.

Comparison to Industry Standards

• The grant of stock options to directors is a standard component of executive and board compensation packages across various industries, including biotechnology, to incentivize long-term commitment and performance.
• The specific exercise price of $0.3598 is relative to Passage BIO's stock valuation at the time of grant and is a common mechanism for aligning director incentives with future stock price appreciation.

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The grant of 143,789 Director Stock Options to Thomas Richard Kassberg, a Director of Passage BIO, Inc., constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align their interests with those of shareholders, potentially leading to improved long-term company performance and shareholder value.
• Employees: No direct impact on general employees is indicated in this filing.

Next Steps

• Monitoring the vesting of the granted stock options as per the specified schedule.
• Observing any future exercises of these options or subsequent sales of the underlying common stock by the director, which would be reported in future Form 4 filings.

Key Dates

Keywords

Passage BIO, PASG, Stock Options, Director, Insider Transaction, SEC Form 4, Equity Compensation, Corporate Governance